Skip to main content
Clinical Trials/DRKS00021182
DRKS00021182
Recruiting
N/A

Evaluation of bone mineral density and bone metabolism during treatment with the januskinaseinhibitor upadacitinib in patients with rheumatoid arthritis

Campus Kerckhoff der Jusuts-Liebig-Universität Gießen, Abteilung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin0 sites60 target enrollmentMarch 26, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Campus Kerckhoff der Jusuts-Liebig-Universität Gießen, Abteilung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin
Enrollment
60
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 26, 2020
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Campus Kerckhoff der Jusuts-Liebig-Universität Gießen, Abteilung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin

Eligibility Criteria

Inclusion Criteria

  • Patients \> 18 years with moderate to severe active rheumatoid arthritis who are going to receive treatment with upadacitinib \[Rinvoq®]. The indication for treatment with upadacitinib needs to be given by the treating rheumatologist. Only patients with RA fulfilling the ACR/EULAR classification criteria are eligible.

Exclusion Criteria

  • Contraindications to treatment with upadacitinib \[Rinvoq®].
  • Incompatible language barriers
  • Missing consent
  • During study: inadherence to pharmacological treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials